Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
LUCA Science Inc. logo — Enabling functional mitochondria as therapeutic agents.

LUCA Science Inc.

Enabling functional mitochondria as therapeutic agents.

Founded 2018 Japan Japan 12 employees Series B Total: $3.87B Biotechnology, Health Care +1

General Information

Company Name LUCA Science Inc.
Founded Year 2018
Location Japan Japan
Founders / Decision Makers
Team member
Employees 12
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with LUCA Science Inc.. To contact LUCA Science Inc., visit luca-science.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does LUCA Science Inc. compare?

A PDF of LUCA Science Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting LUCA Science Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About LUCA Science Inc.

LUCA Science Inc. is a pre-clinical stage biotechnology company that was founded in 2018 with a focus on developing functional mitochondria as therapeutic agents. Their slogan "Enabling functional mitochondria as therapeutic agents" encapsulates their mission. This innovative approach represents an emerging platform in the biotechnology, health care, and pharmaceutical industries with the potential to revolutionize the treatment of damaged tissues and organs. The company is based in Japan. LUCA Science Inc. recently secured a significant ¥3.86B Series B investment on June 6, 2022, with participation from a notable group of investors including 4BIO Capital, Nippon Venture Capital, Nissay Capital, SMBC Venture Capital, Daiwa Corporate Investment, Remiges Ventures, QB Capital, 旭化成ファーマ（株）, NCB Ventures, Fast Track Initiative, Inc. This latest round of funding is indicative of the strong support and confidence that the market has in LUCA Science Inc.'s innovative approach and potential impact in the biotechnology sector.

Business keywords: pre-clinical stage, mitochondria, therapeutic agents, tissue repair, organ repair, cellular therapy, regenerative medicine

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B ¥3.86B 10
4BIO Capital Nippon Venture Capital Nissay Capital
4BIO Capital, Nippon Venture Capital +8
06 Jun 2022
Series A $9.80M -
01 Sep 2020

LUCA Science Inc. Alternatives & Competitors

View All Alternatives
LUCA Science Inc. vs
Noveome Biotherapeutics, Inc.
Noveome Biotherapeutics, Inc. United States

Transforming the way challenging diseases and conditions are treated.

Series E
25 employees
Biotechnology, Health Care
LUCA Science Inc. vs
Angiocrine Bioscience, Inc.
Angiocrine Bioscience, Inc. United States

Transforming medicine through engineered cellular therapies that restore, regenerate, and repair tis...

Grant
21 employees
Biotechnology, Health Care
LUCA Science Inc. vs
ChitogenX
ChitogenX Canada

ChitogenX Inc. is dedicated to the development of novel therapeutic tissue repair technologies to im...

Post-IPO Equity
4 employees
Biotechnology, Health Care
View all alternatives

FAQ About LUCA Science Inc.

Enabling functional mitochondria as therapeutic agents.
LUCA Science Inc. was founded in 2018.
LUCA Science Inc. is headquartered in Japan.
LUCA Science Inc. operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on pre-clinical stage, mitochondria, therapeutic agents and tissue repair.
LUCA Science Inc. has approximately 12 employees.
LUCA Science Inc. has completed 2 funding rounds, raising a total of $3.87B. The latest funding stage is Series B.
Top alternatives and competitors to LUCA Science Inc. include Noveome Biotherapeutics, Inc., Angiocrine Bioscience, Inc., ChitogenX, ClexBio, Bonus Biogroup. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
LUCA Science Inc. and Noveome Biotherapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for LUCA Science Inc., https://bouncewatch.com/company/luca-science-inc, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout